Drugs / AdMSC
AdMSC
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02382874 | May 2015 → Jun 2017 | focal segmental glomerulosclerosis | Royan Institute | Unknown | No outcome recorded |
| Phase 1 | NCT02208713 | May 2014 → Nov 2017 | muscular dystrophy | Royan Institute | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06775964 | Mar 2026 → Jan 2027 expected | cognitive disorder | Paul E Schulz | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06636032 | Mar 2025 → Sep 2027 expected | Crohn disease | University Hospital, Toulouse | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02801890 | Aug 2015 → Feb 2017 | — | Royan Institute | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07326033 | Jan 2026 → Apr 2028 expected | systemic sclerosis | University Hospital, Toulouse | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04356755 | Sep 2020 → Mar 2027 expected | systemic sclerosis | University Hospital, Toulouse | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02107118 Comparator | May 2015 → Mar 2020 | erectile dysfunction, heart disorder | Baylor College of Medicine | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdMSC | “We will evaluate safety and efficacy of intravenous injection of allogeneic AD-MSC (adipose-derived mesenchymal stromal cell) in 5 refractory INS patients.” NCT02382874 ↗7“Evaluation of Autologous Adipose Derived Mesenchymal Stromal Cells (AD-MSC) Transplantation in Ultra Filtration Failure (UFF)” NCT02801890 ↗ “The AD-MSC is prepared from Royan Adipose Tissue Bank.” NCT02208713 ↗ |
| Known as | Adipose Derived Mesenchymal Stem Cells | “Intramuscular Transplantation of Autologous Muscle Derived Stem Cell(MDSC) and Adipose Derived Mesenchymal Stem Cells (AD-MSC) in Patients With Facioscapulohumeral Dystrophy...” NCT02208713 ↗ |
| Known as | adipose stem cells | “ARM 1: AdMSC: adipose stem cells” NCT02107118 ↗ |
| Known as | adipose-derived mesenchymal stromal cell | “We will evaluate safety and efficacy of intravenous injection of allogeneic AD-MSC (adipose-derived mesenchymal stromal cell) in 5 refractory INS patients.” NCT02382874 ↗ |
| Known as | Autologous adipose tissue-derived mesenchymal stem cell | “AdMSC: Autologous adipose tissue-derived mesenchymal stem cell.” NCT02107118 ↗ |
| Known as | CellReady | “AdMSC (CellReady®)” NCT06636032 ↗ |
| Modality | Cell therapy | “AdMSC: Autologous adipose tissue-derived mesenchymal stem cell.” NCT02107118 ↗ |
| Route | Other | “The subject (patient) will receive an infusion of either autologous stem cells (cells made from his own fat tissue) or placebo every 2 weeks for 3 months.” NCT02107118 ↗ |